Search results
Results From The WOW.Com Content Network
Promote safe use of medicines and devices. Manage the Clinical Practice Research Datalink and the British Pharmacopoeia. The MHRA hosts and supports a number of expert advisory bodies, including the British Pharmacopoeia Commission, and the Commission on Human Medicine which replaced the Committee on the Safety of Medicines in 2005. [citation ...
details of appropriate dosage, maximum total dosage, quantity, pharmaceutical form and strength, route and frequency of administration, and minimum or maximum period to administer the medicine; relevant warnings, including potential adverse reactions; details of any necessary follow-up actions; a statement of the records to be kept for audit ...
The Medicines Act 1968 (c. 67) is an act of Parliament of the United Kingdom.Its official long title is "An Act to make new provision with respect to medicinal products and related matters, and for purposes connected therewith."
The Guideline Development Group then finalises the recommendations and the National Collaboration Centre produces the final guideline. This is submitted to NICE to formally approve the guideline and issue the guidance to the NHS. [citation needed] To date NICE has produced more than 200 different guidelines. [27]
The United Kingdom Misuse of Drugs Act 1971 aimed to control the possession and supply of numerous listed drugs and drug-like substances as a controlled substance.The act allowed and regulated the use of some Controlled Drugs (designated CD) by various classes of persons (e.g. doctors) acting in their professional capacity.
The role of therapeutic goods regulation is designed mainly to protect the health and safety of the population. Regulation is aimed at ensuring the safety, quality, and efficacy of the therapeutic goods which are covered under the scope of the regulation. In most jurisdictions, therapeutic goods must be registered before they are allowed to be ...
In the UK, NHS trusts may publish guidelines concerning administration of covert medication. Guidelines often include flowcharts to aid decision making. [16] [17] NICE recommends care home providers have a care home medicines policy that includes guidance on covert administration of medications by care home staff. [18]
The Committee on Safety of Medicines (CSM) was an independent advisory committee that advised the UK Licensing Authority on the quality, efficacy, and safety of medicines. Following the thalidomide tragedy of 1957 to 1961, in 1963 the government asked Sir Derrick Dunlop to set up a committee to investigate the control and introduction of new ...